Additional Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Newport Beach, CA
    Newport Beach CA. 92663
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Yale University School of Medicine
    New Haven CT. 06511
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    University of Kansas Medical Center
    Kansas City MO. 66160
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Henry Ford Health
    Detroit MI. 48202
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Medical University of South Carolina
    Charleston SC. 29425
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Paradigm Clinical Research Centers, LLC
    San Diego CA. 92108
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    UAB Lung Health Center
    Birmingham AL. 35233
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    The Lung Research Center, LLC
    Chesterfield MO. 63017
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    El Paso Pulmonary Association
    El Paso TX. 79902
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Research Institute McGill University Health Center
    Montreal QC. H4A 3J1
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Southern California
    Los Angeles CA. 90033
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Alabama at Birmingham
    Birmingham AL. 35205
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Maryland
    Baltimore MD. 21201
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Inova Healthcare
    Falls Church VA. 22042
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    El Paso Pulmonary Association, P.A.
    El Paso TX. 79902
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Intermountain Medical Center
    Murray UT. 84107
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Temple University Hospital
    Philadelphia PA. 19140
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Summit Health
    Bend OR. 97701
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Hannibal Regional Healthcare System, Inc.
    Hannibal MO. 63401
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Vanderbilt University Medical Center
    Nashville TN. 37204
    View Details